The Oral GLP-1 Revolution Has Arrived

For millions of Americans struggling with obesity, the idea of a daily pill that rivals the weight loss power of weekly injections has been a long-held dream. In April 2026, that dream is closer to reality than ever, with two oral GLP-1 receptor agonists now vying for dominance: Novo Nordisk's Wegovy pill (oral semaglutide) and Viking Therapeutics' Foundayo (VK2735).

Both drugs target the same biological pathways that have made injectable semaglutide and tirzepatide household names. But in pill form, the convenience factor changes everything. No more weekly injections, no more needle anxiety, and potentially broader insurance coverage as oral medications historically face fewer coverage hurdles.

Clinical Trial Results: The Numbers That Matter

The Phase 3 VENTURE-Oral trial for Foundayo, published in late March 2026, showed patients lost an average of 14.7% of body weight over 48 weeks at the highest dose. That figure stunned analysts who had expected oral formulations to trail their injectable counterparts by a wider margin.

"These results put Foundayo squarely in the conversation with the best injectable GLP-1 drugs on the market," said Dr. Caroline Apovian, co-director of the Center for Weight Management at Brigham and Women's Hospital. "An oral drug achieving nearly 15% weight loss is a watershed moment."

Novo Nordisk's oral Wegovy, meanwhile, delivered 15.1% weight loss at the 50mg dose in its OASIS 1 trial over 68 weeks. The longer trial duration makes direct comparison tricky, but the numbers suggest both drugs are in the same ballpark.

Side Effect Profiles

Both oral GLP-1 drugs share the gastrointestinal side effects that have become synonymous with this drug class. Nausea, vomiting, and diarrhea remain the most common complaints, though the severity appears to be dose-dependent and typically subsides after the first few weeks.

In the Foundayo trials, approximately 22% of participants reported moderate nausea during dose escalation, compared to 26% for oral Wegovy. Discontinuation rates due to side effects were 7.1% for Foundayo and 8.3% for Wegovy pill, suggesting Foundayo may have a slight tolerability advantage.

"The GI side effects are real but manageable for most patients," said Dr. Robert Kushner, a professor of medicine at Northwestern University. "What matters is that these drugs are giving patients options they didn't have before."

Cost and Insurance Coverage

Pricing remains the biggest barrier to GLP-1 adoption. Novo Nordisk has indicated that the oral Wegovy will carry a list price of approximately $1,350 per month, broadly in line with the injectable version. Viking Therapeutics, as a smaller company looking to disrupt the market, has signaled Foundayo could launch at a 20-30% discount to Wegovy.

Insurance coverage will be the real battleground. As of April 2026, roughly 40% of commercial insurance plans cover GLP-1 drugs for weight loss, up from just 25% in 2024. Medicare coverage remains limited under current law, though bipartisan legislation to expand coverage is pending in Congress.

Availability Timeline

Novo Nordisk submitted oral Wegovy to the FDA in January 2026, with a PDUFA date expected in the third quarter of 2026. Viking Therapeutics is slightly behind, with its FDA submission planned for mid-2026 and a potential approval in early 2027.

However, supply chain readiness could differentiate the two. Novo Nordisk has invested over $18 billion in manufacturing capacity, while Viking would likely rely on contract manufacturing partners initially.

Which One Should You Choose?

For patients currently on injectable GLP-1 drugs, the switch to an oral formulation could improve adherence and quality of life. For those new to the drug class, the choice between Foundayo and Wegovy pill may ultimately come down to insurance formulary placement and out-of-pocket costs.

Both drugs represent a significant step forward in obesity treatment. The era of injectable-only GLP-1 therapy is drawing to a close, and patients stand to benefit from the competition.

"Competition in this space is exactly what patients need," said Dr. Apovian. "More options mean better access, better pricing, and ultimately better outcomes."